DFO
TLSI icon

Duquesne Family Office’s TriSalus Life Sciences TLSI Stock Holding History

Duquesne Family Office’s Portfolio TLSI Stock Details TLSI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-426,921
Closed -$2.14M – 80
2024
Q4 		$2.14M Hold
426,921
– – 0.06% 76
2024
Q3 		$1.97M Hold
426,921
– – 0.07% 70
2024
Q2 		$2.36M Buy
426,921
+110,966
+35% +$941K 0.08% 58
2024
Q1 		$3.08M Buy
+315,955
New +$2.92M 0.07% 68

Other funds holding TLSI

GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
WAP
Wealthcare Advisory Partners West Chester, Pennsylvania $5.27B AUM 22.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GL
Graypoint LLC Albany, New York $1.78B AUM 16.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Duquesne Family Office's TLSI Position: Q1 2025 in Review

Duquesne Family Office sold out of TriSalus Life Sciences (TLSI) in Q1 2025, closing a stake of 426,921 shares — an estimated $2.14M sold.

Duquesne Family Office first reported a position in TLSI in Q1 2024 and held it in 4 quarters. The position peaked at $3.08M in Q1 2024. 36 funds tracked by Wall St. Rank hold TLSI as of Q1 2025.

  • Duquesne Family Office reported no remaining TriSalus Life Sciences position as of Q1 2025 after selling out during the quarter.
  • Duquesne Family Office sold 426,921 TriSalus Life Sciences shares in Q1 2025, an estimated $2.14M.
  • Duquesne Family Office first reported a position in TriSalus Life Sciences in Q1 2024 and held it in 4 quarters.
  • Duquesne Family Office's TriSalus Life Sciences position peaked at $3.08M in Q1 2024.
  • 36 funds tracked by Wall St. Rank held TriSalus Life Sciences as of Q1 2025.

Based on Duquesne Family Office's 13F filing for Q1 2025, filed 15 May 2025.